# FAQ — Research Peptide Fundamentals — aminopeptides.co

> Frequently asked questions about BPC-157, retatrutide, and tesamorelin: mechanisms, regulatory status, evidence, and cautions. Plain-language answers with citations.

Plain answers to the questions that come up most often. Citations included.

## What does BPC-157 do in the body?

In animal models, BPC-157 primarily stimulates angiogenesis — the growth of new blood vessels into damaged tissue — via the VEGFR2-Akt-eNOS pathway [4]. Secondary effects documented in animals include modulation of serotonin and dopamine systems, sensitization of growth hormone receptor in tendon cells, and enhancement of cell migration. In humans, evidence is limited to three small pilot reports as of 2025; no large controlled trials have been completed [2]. What it does in human tissue is not yet established at that resolution.

## Is BPC-157 a growth hormone?

No. BPC-157 is a pentadecapeptide — a fifteen-amino-acid chain derived from a sequence in gastric juice protein — and has no structural or receptor-level relationship to growth hormone. It is not a hormone at all in the pharmacological sense. Some animal studies show it sensitizes the growth hormone receptor in tendon fibroblasts, but that is a downstream effect on a receptor, not the peptide itself being or releasing growth hormone. These are distinct mechanisms.

## Does BPC-157 work immediately?

Pharmacokinetic data in rats and dogs show a very short elimination half-life — under 30 minutes — meaning the intact peptide is largely cleared from circulation within hours [3]. Animal healing studies measure outcomes over days to weeks. How quickly any biological effect begins in humans, and whether "immediate" effects reported anecdotally reflect direct pharmacology or other factors, cannot be answered from the current human data, which is limited to a two-person safety pilot [1].

## Does BPC-157 damage the liver?

There is no evidence in the published literature of BPC-157 causing liver damage. The 2025 first-in-human IV safety pilot in two adults showed no measurable changes in hepatic biomarkers [1]. A 2025 narrative review, while cautioning that the human dataset is very small, does not identify hepatotoxicity as a documented concern [2]. The honest answer is that the human evidence is too thin to make a confident claim either way — the absence of harm signals in two patients is not the same as established hepatic safety.

## What does retatrutide do?

Retatrutide activates three receptor systems simultaneously — GIP, GLP-1, and glucagon — to reduce appetite, improve glucose-dependent insulin secretion, and increase energy expenditure through the glucagon arm [7]. In Phase 2 clinical trials in humans with obesity, it produced a mean 24.2% body-weight reduction at 48 weeks at the highest dose versus 2.1% with placebo [9]. It also substantially reduced liver fat in participants with metabolic liver disease [8]. It is an investigational compound, not an approved drug.

## How does retatrutide work?

Retatrutide is a single 39-amino-acid peptide that simultaneously occupies the GLP-1 receptor, the GIP receptor, and the glucagon receptor. GLP-1 receptor activation slows gastric emptying and suppresses appetite; GIP receptor activation (at approximately 8.9× the potency of native GIP) augments insulin secretion; glucagon receptor activation raises energy expenditure thermogenically and mobilizes stored fat [7]. Cryo-EM structural studies resolved retatrutide binding to each receptor at near-atomic resolution, confirming the triple-engagement mechanism [7]. The three-arm combination is what drives larger weight reduction than single or dual incretin agents showed in comparable trials [6].

## How to reconstitute retatrutide?

This desk does not provide reconstitution protocols. Retatrutide is an investigational compound not approved for general human use; outside a clinical trial there is no validated preparation protocol, no verified source material, and no clinical oversight for administration. Publishing reconstitution instructions would be offering operational guidance for unapproved self-administration, which this site does not do. If you are enrolled in a clinical trial, reconstitution is handled per the trial's investigational brochure under site pharmacist supervision.

## Is retatrutide FDA approved?

No. Retatrutide is investigational. As of mid-2026, it remains in Phase 3 trials (the TRIUMPH program) [6]. No regulatory agency has approved it as a prescription drug or consumer product. Phase 2 results were published in 2023 and showed substantial efficacy in obesity and type 2 diabetes [9][10], but Phase 2 completion does not constitute approval. The FDA and other regulators make approval decisions after reviewing Phase 3 data, manufacturing standards, labeling, and risk management plans.

## What is tesamorelin?

Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone (GHRH). It is modified at the N-terminus with a trans-3-hexenoic acid group, which makes it resistant to the enzyme (DPP-IV) that rapidly degrades natural GHRH. The FDA approved tesamorelin in 2010 to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, a condition in which antiretroviral therapy causes abnormal fat redistribution [14]. Outside that approved indication, tesamorelin is off-label.

## What does tesamorelin do?

In its FDA-approved indication, tesamorelin reduces visceral adipose tissue — the abdominal fat surrounding the organs — in adults with HIV-associated lipodystrophy. Across five RCTs pooled in a 2026 meta-analysis, it reduced VAT by a mean of 27.71 cm² and hepatic fat fraction by 4.28%, while increasing lean body mass by 1.42 kg, without serious adverse events [13]. Visceral fat reaccumulates when dosing stops [17]. In healthy men, it raises GH and IGF-1 without significantly altering insulin sensitivity [16].

## How does tesamorelin work?

Tesamorelin binds the GHRH receptor on pituitary somatotroph cells, triggering the Gs-cAMP-PKA cascade that causes the pituitary to synthesize and secrete growth hormone in a pulsatile pattern [17]. The resulting GH drives hepatic IGF-1 production. GH and IGF-1 together promote lipolysis — fat breakdown — preferentially in visceral adipose tissue. By acting on the receptor upstream rather than delivering GH directly, tesamorelin preserves the body's own pulsatile GH rhythm, which appears to spare insulin sensitivity compared to exogenous GH administration [16].

## Will tesamorelin help me lose belly fat?

In HIV-positive adults with antiretroviral-induced lipodystrophy — the specific approved population — yes, the evidence is consistent and substantial [13][15][17]. In people without HIV-associated lipodystrophy, there are no large randomized controlled trials establishing efficacy, and using tesamorelin for that purpose is off-label and investigational. A GHRH analogue raising GH and IGF-1 plausibly promotes lipolysis through mechanism, but that is not the same as demonstrated efficacy in a general population, and the FDA approval does not extend there. This site does not advise on individual treatment decisions.

---

An austere digest of published research — mechanism, species, and outcome, exactly as the literature reports them.